bluebird bio Inc (BLUE.OQ)
27 Feb 2017
FRANKFURT German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.
Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.
* Says HGB-207 and all studies of lentiglobin to incorporate manufacturing process 2 going forward
* Bluebird Bio provides update on Lentiglobin programs and research and development strategy at gene therapy day
BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program
* LentiGlobin(TM) investigational gene therapy for transfusion-dependent beta-thalassemia accepted into European Medicines Agency's PRIME program Source text for Eikon: Further company coverage: